Skip to content

Zevra Therapeutics, Inc. ZVRA Operating Lease Liability Payments - 2026 (Lessee)

Operating Lease Liability Payments - 2026 (Lessee) at other companies

Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$2.95M+26.6%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$1.54M+9.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$36.2M+77.5%
Gross profit$34.3M+80.1%
Operating income$52.1M+1,073%
Net income$37.9M+1,323%
EPS (diluted)$0.60+1,100%

Balance sheet

See full
Cash & equivalents$95.6M+156%
Total debt$1.1M-98.1%
Total equity$205.8M+402%
Total assets$278.6M+61.3%

Cash flow

See full
Operating cash flow$6.1M+175%
CapEx$35.0K-64.6%
Free cash flow$6.1M+173%

Valuation

See full
Market cap$782.09M+58.2%
Enterprise value$687.64M+32.5%
P/E6.3×
P/S6.4×-5.8×

Profitability

See full
Gross margin86.1%+7.2pp
Operating margin-103.9%-43.0pp
Net margin101.6%+60.1pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity100.7%+60.3pp
Debt / equity-1.5×
Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s operating lease liability payments - 2026 (lessee).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s operating lease liability payments - 2026 (lessee)?
Zevra Therapeutics, Inc. (ZVRA) reported operating lease liability payments - 2026 (lessee) of $41K in Q1 2026.
What does operating lease liability payments - 2026 (lessee) mean?
This represents the specific cash outflow commitment for operating leases scheduled for the calendar year 2026. It allows investors to isolate the impact of real estate and equipment lease obligations on the company's cash flow in a specific future period.